Biotinylated Human FcRL2/IRTA4 Protein (Primary Amine Labeling)
Catalog No: IRTA4-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human FcRL2/IRTA4 Protein (Primary Amine Labeling) is expressed in HEK293 cells with a His tag at the C-terminus. It contains amino acid residues Leu20-Val401 (UniProt accession: Q96LA5-1).
Product Details
- Molecular Aliases
- FcR-like protein 2; FcRL2; FCRH2; IFGP4; IRTA4; FCRL2; CD307b; FCRH2SPAP1B; IRTA4SPAP1C; SPAP1; SPAP1A
- Protein Length
- Leu20-Val401
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 42.7 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Biotinylated Human FcRL2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Biotinylated Human FcRL2, His Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-FcRL2 Antibody, hFc Tag with the EC50 of 28.2ng/ml determined by ELISA (QC Test).
Background
Fc receptor-like 2 (FCRL2) is highly expressed on B-cell chronic lymphocytic leukemia (B-CLL) cells and could possibly influence disease pathogenesis. FCRL2 mRNA expression was found to be expressed at considerably higher levels in peripheral blood mononuclear cells (PBMC) of B-CLL patients compared to controls (range 1.35- to 210-fold upregulation; P < 0.0001) and cells of other hematological diseases.
References
- Nückel H, Collins CH, Frey UH, Sellmann L, Dürig J, Siffert W, Dührsen U. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia. Eur J Haematol. 2009 Dec 1;83(6):541-9. doi: 10.1111/j.1600-0609.2009.01328.x. Epub 2009 Aug 4. PMID: 19682311.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.